TLPH
TALPHERA, INC.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.08
+0.00%Research · Aug 25, 2026
CRRT Anticoagulation Adds Nafamostat as Fallback in Draft KDIGO Guidelines
The draft KDIGO acute kidney injury guideline raises regional citrate to 1B and names nafamostat as a fallback, a protocol most US ICUs do not run today.